REG - hVIVO plc - Directorate Change

hVIVOAnnouncement

08/10/2018 07:05

RNS Number : 2023D
hVIVO plc
08 October 2018
 


hVIVO plc
("hVIVO" or the "Company")
 
Directorate change
 
London, UK, 8 October 2018: hVIVO plc (AIM: HVO), announces that Jaime Ellertson has notified the Company of his intention to step down as a Non-Executive Director and he will leave the Board of the Company with immediate effect. Jaime joined hVIVO as Non-Executive Chairman on 12 June 2014 and was succeeded by Trevor Phillips as Executive Chairman on 13 November 2017, but remained as a Non-Executive Director.
 
Trevor Phillips, Executive Chairman of hVIVO, said: "On behalf of the Board, I would like to thank Jaime for his contribution and advice over the past four years.  We wish him well for the future in pursuing his significant other interests."
 
 
- Ends -
 
For further information please contact:
 



hVIVO plc


+44 207 756 1300




Trevor Phillips (Executive Chairman)








Fleur Wood (EVP, Investor Relations & Communications)


















Numis Securities Limited


 +44 207 260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)








James Black / Michael Burke (Corporate Broking)


















FTI Consulting








Simon Conway / Victoria Foster Mitchell


+44 203 727 1000



 
About hVIVO plc
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAMMMGGNNFGRZG